DOCSLIB.ORG

15 Mladen Nisavic, M.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
15 Mladen Nisavic, M.D Patients With Substance Use Disorders 15 Mladen Nisavic, M.D. Shamim H. Nejad, M.D. OVERVIEW readiness for recovery), identification of outpatient addiction resources, and use of medications to reduce craving and to Without a doubt, substance use disorders (SUDs) present maintain recovery. The chronic, relapsing, nature of sub- one of the gravest difficulties currently facing the United stance use may inspire resignation and hopelessness in States healthcare system. Over the past two decades, the consulting clinicians, leading to a misperception that the number of patients treated for substance use-related problems consultation is unnecessary, or even futile. Because most in the United States has grown steadily, and over the past clinicians fail to appreciate that the relapse rate for other 5 years it has reached epidemic proportions. Data from the common chronic medical disorders (e.g., diabetes, hyperten- Centers for Disease Control and Prevention (CDC) indicate sion, asthma) exceeds that for SUDs, they do not treat that in the 10 years between 2004 and 2014, the mortality substance abuse patients with comparable therapeutic dili- rates attributed to drug overdoses increased by 137%, gence.3 The Massachusetts General Hospital (MGH) has including a staggering 200% increase in the rate of overdose dedicated considerable effort and resources to adequately deaths attributed to opioids. The increased mortality rates address the substance use epidemic within our local com- were independent of sex, age group, or ethnicity, and were munities, starting with a hospital-wide effort to ensure that evident across the country. In fact, the CDC estimates that problems related to substance use are addressed with the nearly half a million persons in the United States died from same degree of compassion and persistence directed at other drug overdoses between 2000 and 2014, and that drug-related common relapsing medical disorders. Medical and surgical fatalities were one and a half times higher than deaths from hospitalizations often provide extended periods during which motor vehicle crashes in 2014.1 Up to 80% of all drug-related patients are separated from their substance use, and thus fatalities appear to be unintentional, with 13% attributed hospitalization may present a unique opportunity to engage to suicide, and the remainder classified as undetermined. the patient in meaningful interventions. The increase in drug use has also led to increased utiliza- tion of healthcare services. The Drug Abuse Warning Network (DAWN) and the Substance Abuse and Mental Health Service Administration (SAMHSA) estimate that over 5 million Emergency Department (ED) visits in 2011 CASE 1 were related to drug use—a 100% increase over their 2004 Mr. B, a 36-year-old homeless man with a history of sub- data. Of these, nearly 2.5 million ED visits were attributed stance use and abuse (benzodiazepines, opiates, and to medical emergencies related to drug abuse. stimulants), was admitted to the vascular surgery service Clinical presentations in this domain are also becoming with ischemia to his right hand and forearm. The injury more complex. Of the 2.5 million ED visits identified by was sustained when he relapsed on “heroin” (after 2 months DAWN/SAMHSA in 2011, nearly one-half involved of recovery), and became obtunded with a protracted complications related to use of prescription medications, period of immobility. An initial urine toxicology screen with the remainder being attributed to use of non-prescription was positive for benzodiazepines and opioids, with further illicit drugs. While the use of opioids, marijuana, and cocaine toxicology testing that confirmed the presence of clonaz- are seen most commonly, more than 50% of the patients epam, methadone, and fentanyl. Psychiatric consultation present with co-ingestion of multiple substances, and there was requested to assist with pain management and to has been an increase in use of CNS stimulants, “club drugs,” provide assistance with addiction recovery treatment and hallucinogens.2 referral and resources. Successful treatment of this expanding group of patients On interview, Mr. B was alert, oriented, lucid, and requires that clinicians improve their management skills for forthcoming. He reported surprise, and then frank fear, SUDs and their sequelae. This involves timely and correct that he “ended up this way—after all I only used once.” He diagnosis of the substance use problem, recognition of also appeared surprised that the toxicology screen revealed key symptoms associated with intoxication or acute evidence of fentanyl and benzodiazepines, as he was discontinuation/withdrawal, and appropriate initial manage- “certain” he used heroin. He complained of pain, despite ment and treatment. It also involves meaningful engagement being on his methadone maintenance (75 mg/day), and (including motivational enhancement techniques to assess 149 Downloaded for Anonymous User (n/a) at Uniformed Services Univ of the Health Sciences from ClinicalKey.com by Elsevier on September 16, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved. 150 Chapter 15 Patients With Substance Use Disorders neutralization by the acidic milieu of the stomach). More expressed concern that his pain would be under-treated commonly, cocaine is injected, insufflated or inhaled (as because of his history of substance use. His mood was “crack”) as the latter methods greatly increase the bioavail- appropriate to the clinical context: there was no evidence ability of the drug. of depression. Following initial stabilization, Mr. B underwent amputa- Pharmacology and Mechanism of Action tion of his right forearm and hand. During the perioperative Cocaine increases the monoamine neurotransmitter activ- period, he received a combination of long-acting opioids ity in the central nervous system (CNS) by blocking the for basal analgesic control, as well as short-acting opioids pre-synaptic re-uptake transporters for dopamine, norepi- for breakthrough pain. His methadone dose was increased nephrine, and serotonin. Given the potent effects of cocaine to 90 mg/day, and was split into three-times-a-day dosing on dopamine’s availability within the CNS, much of the to optimize pain management. His short-acting opioids drug’s stimulant and addictive effects have been ascribed (intravenous [IV], then oral hydromorphone) were tapered to its effects on the corticomesolimbic dopamine reward gradually over 2 weeks while he remained in the inpatient circuits.5,6 In addition to these effects, cocaine also acts by setting. blocking voltage-gated sodium ion channels, an action that With improved pain control, Mr. B more readily engaged accounts for its effect as a local anesthetic and contributes in readiness work via motivational interviewing and he to its cardiac toxicity. accepted addiction recovery services. He identified The route of administration greatly influences the methadone maintenance as a key element to his recovery bioavailability of the drug, including its onset and duration and noted no cravings on the higher dose of his medication. of intoxication. Smoking (i.e., inhalation) and IV use gener- He found inspiration in his survival, and despite grieving ally lead to near instantaneous (seconds to minutes) effects, the loss of his limb, expressed a strong readiness to maintain and most patients note that the drug’s effects wear off within recovery. He worked closely with the consultation team 30 minutes. Intranasal administration results in slower onset to identify triggers for relapse and secured a safe disposition of symptoms (within 30 minutes) and the effects of the drug plan. By the end of his 2-week hospital stay, Mr. B held are similarly extended to up to 1 hour. regular meetings with Narcotics Anonymous (NA) peers Cocaine is commonly co-administered with alcohol, in the hospital. He maintained continuous contact with which leads to the formation of cocaethylene, a compound his methadone provider and allowed the consultation team with stimulant effects similar to that of cocaine, albeit with to share their impressions with the clinic. a longer half-life. This compound has also been noted to Mr. B was discharged to his parents’ home, with a plan to carry greater cardiac toxicity compared with cocaine alone. follow-up with his methadone clinic and NA. He expressed Cocaine is extensively metabolized by the liver, and its (appropriate) anxiety on discharge, as he readily admitted metabolites are eliminated in the urine, most commonly as that the road ahead of him would be challenging, but also benzoylecgonine. This metabolite (rather than the parent noted hope and readiness to battle his addiction. compound) is detected by urine drug tests for cocaine; it can be detected as early as 4 hours after intake, and may remain detectable for up to 1 week after cocaine is used. There are STIMULANTS no common false positives for urine cocaine screen. Cocaine Cocaine intoxication is associated with potent stimulant effects, including increased energy and alertness, bright (to Cocaine is a tropane alkaloid naturally found in leaves of frankly euphoric) affect, insomnia, as well as anorexia. Similar the Erythroxylum coca plant, a bush native to the Andes to other stimulants, cocaine is associated with an intensely Mountains region of South America. To this day, leaves of pleasurable state and is commonly used to potentiate sexual the plant continue to be used by the indigenous people activity. With
Load more

Recommended publications
  • The Ethics of Psychedelic Medicine: a Case for the Reclassification of Psilocybin for Therapeutic Purposes
    THE ETHICS OF PSYCHEDELIC MEDICINE: A CASE FOR THE RECLASSIFICATION OF PSILOCYBIN FOR THERAPEUTIC PURPOSES By Akansh Hans A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Bioethics Baltimore, Maryland May 2021 © 2021 Akansh Hans All Rights Reserved I. Abstract Our current therapeutic mental health paradigms have been unable to adequately handle the mental illness crisis we are facing. We ought to ‘use every tool in our toolbox’ to help individuals heal, and the tool we should be utilizing right now is Psilocybin. Although it is classified as a Schedule I drug, meaning that it is believed to have a high potential for abuse, no accepted medical uses, and a lack of safety when used under medical supervision, Psilocybin is not addictive and does not have a high potential for abuse when used safely under medical supervision. For these reasons alone, Psilocybin deserves a reclassification for therapeutic purposes. However, many individuals oppose Psilocybin-assisted psychotherapy on ethical grounds or due to societal concerns. These concerns include: a potential change in personal identity, a potential loss of human autonomy, issues of informed consent, safety, implications of potential increased recreational use, and distributive justice and fairness issues. Decriminalization, which is distinct from reclassification, means that individuals should not be incarcerated for the use of such plant medicines. This must happen first to stop racial and societal injustices from continuing as there are no inherently ‘good’ or ‘bad’ drugs. Rather, these substances are simply chemicals that humans have developed relationships with. As is shown in this thesis, the ethical implications and risks of psychedelic medicine can be adequately addressed and balanced, and the benefits of Psilocybin as a healing tool far outweigh the risks.
    [Show full text]
  • Hallucinogens
    Hallucinogens What Are Hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and others are synthetic (human-made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes. Hallucinogens are a Types of Hallucinogens diverse group of drugs Classic Hallucinogens that alter perception, LSD (D-lysergic acid diethylamide) is one of the most powerful mind- thoughts, and feelings. altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other Hallucinogens are split grains. into two categories: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) comes from certain classic hallucinogens and types of mushrooms found in tropical and subtropical regions of South dissociative drugs. America, Mexico, and the United States. Peyote (mescaline) is a small, spineless cactus with mescaline as its main People use hallucinogens ingredient. Peyote can also be synthetic. in a wide variety of ways DMT (N,N-dimethyltryptamine) is a powerful chemical found naturally in some Amazonian plants. People can also make DMT in a lab.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Defining Clinical Issues Around Tolerance, Hyperalgesia, And
    ORIGINAL ARTICLE Defining clinical issues around tolerance, hyperalgesia, and addiction: A quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice Jennifer P. Schneider, MD, PhD; Kenneth L. Kirsh, PhD ARTICLE INFO ABSTRACT Keywords: Treatment with opioid medications has grown over the past decades, but has been tolerance surrounded by some ongoing controversy and debate to whether it is causing more dependence opioids harm than good for patients. To this end, the field of pain management has suf- hyperalgesia fered from a lack of clarity about some basic definitions on concepts such as toler- long-term opioid therapy ance and hyperalgesia. Some characterize these issues as inevitable parts of opioid therapy while other schools of thought look at these issues as relatively rare occur- Article history: rences. Unfortunately, most of the rhetoric around these topics has occurred with Received 13 February 2010 very little in the realm of real world data. To this end, the authors have reviewed Received in revised form 26 July 2010; the charts of 197 patients treated by a pain specialist for at least 1 year to better 30 August 2010 Accepted 31 August 2010 illustrate whether notions of tolerance and hyperalgesia are common occurrences DOI:10.5055/jom.2010.0036 and, more importantly, whether they occur within any type of specified timeframe. A total of 197 patient charts were reviewed. The sample had an average age of 49.39 years (range ϭ 19-87 years; standard deviation [SD] ϭ 12.48) and com- prised 66 men (33.5 percent) and 131 women (66.5 percent).
    [Show full text]
  • Hallucinogens
    Hallucinogens What are hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their own thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and some are synthetic (human- made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes, including to have fun, deal with stress, have spiritual experiences, or just to feel different. Common classic hallucinogens include the following: • LSD (D-lysergic acid diethylamide) is one of the most powerful mind-altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other grains. LSD has many other street names, including acid, blotter acid, dots, and mellow yellow. • Psilocybin (4-phosphoryloxy-N,N- dimethyltryptamine) comes from certain types of mushrooms found in tropical and subtropical regions of South America, Mexico, and the United States. Some common names for Blotter sheet of LSD-soaked paper squares that users psilocybin include little smoke, magic put in their mouths. mushrooms, and shrooms. Photo by © DEA • Peyote (mescaline) is a small, spineless cactus with mescaline as its main ingredient. Peyote can also be synthetic.
    [Show full text]
  • Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics
    December 6, 2000 NIDA-CTN-0007 MOTIVATIONAL INCENTIVES FOR ENHANCED DRUG ABUSE RECOVERY: METHADONE CLINICS Maxine Stitzer, Ph.D., Lead Investigator Nancy Petry, Ph.D. Co-Lead Investigator Robert Brooner, Ph.D. Co-Investigator Jessica Peirce, Project Coordinator Protocol work group: Nancy Petry New England Paul McLaughlin New England Richard Rawson Pacific Frank Flammino Pacific Bob Forman Delaware Valley Peter Barbur Northwest Sara Lamb Northwest Scott Kellogg New York Elaine Pencer New York Jack Blaine NIDA NIDA-CTN-0007 Motivational Incentives: Methadone Clinic 1 Version 6, Date December 6, 2000 December 6, 2000 TABLE OF CONTENTS 1 LIST OF ABBREVIATIONS................................................................................................. 3 2 PROTOCOL SUMMARY...................................................................................................... 4 3 BACKGROUND AND SIGNIFICANCE.............................................................................. 7 4 STUDY OBJECTIVE........................................................................................................... 10 5 SUSTAINABILITY WITHIN THE CTP’S ........................................................................ 10 6 STUDY DESIGN.................................................................................................................. 11 6.1 Drug targets....................................................................................................................... 11 6.2 Bonus incentive targets: opiates.......................................................................................
    [Show full text]
  • Collision of COVID-19 on Opioid Overdose and Treatment
    Emerging Issues in the Opioid Crisis Nora D. Volkow, M.D. Director National Institute on Drug Abuse @NIDAnews Overdose Deaths in 2019 Increased by 4.6% Number of Deaths Number of Deaths 40,000 Fentanyl, 37,137 18,000 Prescription opioids, 14,347 Methamphetamine, 16,539 35,000 16,000 Heroin, 14,278 Cocaine, 16,196 30,000 14,000 12,000 25,000 10,000 20,000 8,000 15,000 6,000 10,000 4,000 5,000 2,000 0 0 Overdose Death Rates: Other Synthetic Narcotics (Including Illicit Fentanyl) 2013 2018 Source: CDC WONDER. Age-adjusted death rates per 100,000. Overdose Death Rates: Psychostimulants With Abuse Potential (Including Methamphetamine) 2013 2018 Source: CDC WONDER. Age-adjusted death rates per 100,000. Intersection Between Opioid Crisis and COVID-19 ` Overdoses Grew Dramatically During COVID Pandemic ST Drug Use Increase During COVID Total US Increase 31.96% 19.96% 10.06% 12.52% 7 Millennium Health Signals Report™ COVID-19 Special Edition: Significant Changes in Drug Use During the Pandemic Volume 2.1 | Published July 2020 Total Study Population Change in Unadjusted Positivity Rate for Cocaine, Fentanyl, Heroin and Methamphetamine COVID-Related Policy Changes for Prescribing Medications for OUD Methadone Buprenorphine Prior to COVID: Prior to COVID: • Only federally-approved opioid • Prescribed through pharmacies in outpatient treatment programs settings • In-person for daily dosing • DATA 2000, limited to clinicians with bup. waivers that required additional training and Under COVID, SAMSHA allowed: federal registration • 3/16/2020: 28 day
    [Show full text]
  • Appendix 1 – Data Code Values
    Florida Department of Children and Families Substance Abuse and Mental Health Financial and Services Accountability Management System (FASAMS) Pamphlet 155-2 Appendix 1 Data Code Values Last Revision Date: 10/01/2021 Effective Date: 7/01/2021 Version 14.0 Pamphlet 155-2 Appendix 1, Version 14.0 Last Revision Date 10/01/2021 Effective Date: 7/01/2021 Page 1 of 64 Table of Contents 1 State/Province ................................................................................................................................................................ 3 2 County Area .................................................................................................................................................................... 4 3 Covered Service .............................................................................................................................................................. 5 4 Service Category ............................................................................................................................................................. 9 5 Project Codes .................................................................................................................................................................. 9 6 Project Codes, Method of Payment and Unit of Measure ........................................................................................... 13 7 FY 2021-22 Active OCA Codes ......................................................................................................................................
    [Show full text]
  • Wisconsin Opioid Treatment Program Patient Reference Handbook
    WISCONSIN Opioid Treatment Program PATIENT REFERENCE HANDBOOK Department of Health Services Division of Care and Treatment Services Bureau of Prevention Treatment and Recovery P-23048 (09/2016) WELCOME Congratulations on taking the first step into treatment and long-term recovery from your addiction! At this point, you may be unsure of how treatment works and what to expect. This book is designed to provide you and your loved ones answers to questions you may have concerning treatment. Please note that this book is a reference tool to use. If you have questions after reading this handbook, please make sure to ask a staff person. The information that is provided in this handbook should be seen as guidelines for narcotic treatment clients. This handbook provides guidance of often difficult to understand state and federal regulations. Further, this guidance should not be construed as providing rigid answers, except in those areas where state or federal laws exist. Please refer to individual clinic policies and procedures if you have questions or are unsure of the rules when it comes to medication-assisted treatment. Life is very interesting...in the end, some of your greatest pains become your greatest strengths. Drew Barrymore Quote for Overcoming Addiction Wisconsin Department of Health Services Division of Care and Treatment Services Bureau of Prevention Treatment and Recovery State Opioid Treatment Authority 1 West Wilson Street Room 850 Madison WI 53703 October 2011 Revised September 2016 OPIOID TREATMENT SERVICE – PATIENT REFERENCE
    [Show full text]
  • Hallucinogens Hallucinations
    Hallucinogens Hallucinations Affect a person’s: Perceptions Sensations Thinking Self-awareness Emotional state Synesthesia Transposition of senses: Seeing sounds Hearing colors Flash Back Vivid recollection of hallucinogenic experience Emotional “Bad trip” (Panic, fear, etc.) Somatic Altered body sensations, tremors, weakness, dizziness, crawly, tingling feeling on the skin Perceptual Distortions of the five senses Psychotomimetic Something that mimics psychosis Delusion A false belief Illusion A false perception Natural Hallucinogens Peyote (Mescaline) Psilocybin Natural Hallucinogens Jimson Weed Bufo Alvarius Natural Hallucinogens Morning Glory Seeds Nutmeg Natural Hallucinogens Salvia Divinorum Synthetic Hallucinogens LSD (Lysergic Acid Diethylamide) MDMA “Ecstasy” (3, 4 Methylenedioxymethamphetamine) Methods of Ingestion Orally Smoked Transdermal Insufflation Injection General Indicators Varies and influenced by personality, mood, expectations and surroundings of user Depressed = deeper depression Pleasant = heightened pleasure Can uncover emotional flaws Bad “trip” Effects Hallucinations Body tremors Paranoia Uncoordinated Nausea Disoriented Perspiring Memory loss Difficulty in speech Flashbacks Synesthesia Poor time perception Dazed appearance Onset and Duration - Peyote 30 minutes: Onset Nausea, elevated blood pressure, pulse and temperature and dilated pupils 60 minutes: Begin hallucinogenic effects Visual distortions, rich colors, changing forms and moving shapes 3-4 hours: Peak effects “Synesthesia”
    [Show full text]
  • Technology for Drug Testing
    If you have issues viewing or accessing this file, please contact us at NCJRS.gov. Aud,OTeleconlerence Packet Technology for Drug Testing November 17, 1998 2:30 - 4:00 p.m. (EST) F'ROr:'t::~"~ ~ '~ ,.jr: National Criminal Justice Releronce Service (~NOJ.R..~).,, ,~..~ ... Box 6000 .... "-- Rockville, ME) 20849 °6000i'~~ ............ Kevin Jackson Saralyn Borrowman Presenters Provided by the American Probation and Parole Association Funded by the Office of Juvenile Justice and Delinquency Prevention © ® Prepared under Award No. 98-JB-VX-0103 from the Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U. S. Department of Justice. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the U. S. Department of Justice. © TECHNOLOGY FOR DRUG TESTING Training Objectives As a result of this teleconference, participants will be able to: • Name six types of technology for substance abuse testing and describe the relative advantages and disadvantages of each. • Describe the difference between immunoassay and chromatography testing for urine. • List the classifications of substances that can be detected through urine testing and those for which tests are either unavailable or require more difficult or costly testing methods. • Identify ways that urine tests can be adulterated or otherwise tampered with and ways to detect and/or avoid these problems. • Make decisions for program policies and procedures regarding onsite or off site testing, instrument or noninstrument testing, drugs to test for, scheduled or random testing, frequency of testing, specimen collection procedures, chain of custody procedures, confirmation tests, cutoff levels; and • Specify how positive and negative results will be used ABOUT THE PRESENTERS Kevin Jackson Saralyn Borrowman National Institute of Justice Office of Science and Technology Washington, D.C.
    [Show full text]